Japan-based Kidswell Bio and global health care asset advisor Treehill Partners have created a new regenerative medicine company, Kidswell USA, with the aim of accelerating development of Kidswell’s cell therapy pipeline, currently targeting cerebral palsy (CP) as a lead indication.
Kidswell is pioneering the development of stem cells derived from human exfoliated deciduous teeth (SHED) as a regenerative therapy platform. The company’s lead program, SQ-SHED, has shown strong initial signals of clinical efficacy in CP.
Last month, Kidswell subsidiary, S-Quatre, released a joint research paper with Nagoya University demonstrating therapeutic efficacy in animal models of cerebral palsy even when treatment with SHED is initiated during the chronic phase where neurological symptoms have already become apparent. Furthermore, the study systematically elucidated key aspect of the underlying mechanism responsible for this therapeutic effect.
In the new company, Kidswell and Treehill will work to advance SQ-SHED through clinical development in the most cost-effective format, and with a specific focus on the U.S. market. Senior management will be provided by Treehill and the partners have selected Thermo Fisher Scientific as their preferred development service partner.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!